Public and private organizations are making huge investments in protein-based research and development (R&D). In recent past, the development of monoclonal antibodies and proteins as therapeutic agents was avoided by pharmaceutical firms, on account of their size, poor delivery, low stability, and rate of degradation. However, the companies are focusing on the development of proteins and monoclonal antibodies as therapeutics to address the unmet requirements in several therapeutic areas, including oncology, metabolic diseases, cardiovascular disorders, and infectious diseases. This has increased the usage of proteins that imitate the functions of mediators.
Several key players in the protein A resin market have been involved in partnership and collaboration activities with the aim to develop advanced next-generation protein A resins and launch novel products. For example, Bio-Works Technologies AB signed a distribution agreement with Gene Company Ltd., a Hong Kong-based company, in October 2019. According to the terms of this agreement, Gene Company Ltd. would import, store, promote, market, distribute, and sell products manufactured by Bio-Works Technologies AB.
Globally, the North American protein A resin market generated the highest revenue in 2019, due to the escalating adoption of protein-based therapeutics for triatic critical medical conditions and soaring number of the Food and Drug Administration (FDA) approvals for biopharmaceuticals in the region. Additionally, strong presence of large-scale drug manufacturers like Bayer AG and Gilead Sciences Inc. and the expansion of biopharma research sector are also supporting market growth. The U.S. is the larger contributor to the regional market, on account of rising incidence of chronic diseases and increasing number of protein-related R&D activities.
Whereas, the Asia-Pacific (APAC) market will register the fastest in the coming years, on account of the growing usage of protein A resins in drug recovery and increasing frequency of life sciences research activities. Moreover, continuous advancements in technologies will also boost the usage of protein A resins in the region. Japan is the leading contributor to the APAC market, as the country hosts some of the pharmaceutical giants like Takeda Pharmaceutical Co. Ltd., Otsuka Holdings Co. Ltd., and Astellas Pharma Inc. and invests heavily in R&D activities to develop advanced drugs.
Get More details Protein A Resin Market Business Opportunities
